Clinical Trial Search

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560

Primary: Frequency of Treatment-emergent Adverse Events (Safety) — 8; 3 Participants

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134

Primary: Safety: Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 21; 10 Participants

Primary: Acute Safety — 2 participants

Primary: Number of Participants That Completed Patient Quality of Life Survey — 4; 3; 3; 3 Participants

Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819

Primary: Overall Summary of Adverse Events (AEs) — 67.65; 47.06; 7.06; 0.59 Percentage of participants

Primary: Safety: Treatment-emergent Adverse Events and Serious Adverse Events for All Randomized Subjects Who Received Any Study Medication — 15; 13; 4; 4 number of events

Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1

Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522

Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale

Primary: Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version) — 2.3; 5.22 units on…

Primary: Changes in Executive Function as Measured by the NIH EXAMINER Computer Battery — -0.06; -0.14 score on a scale — p=0.55

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 16 After Cessation of Study Drug — 6.4; 12.5; 10.5 units on a scale

Primary: Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale…

Primary: Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF) — -0.4; 2.2 Units on a scale — p=0.001

Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline — 1.251; 0.8741 fold change…

Primary: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline — 1.1; .9 score on a scale

Primary: Number of Participants With Evaluable fMRI Scans — 9; 9; 9; 9 participants

Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12

Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095

Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67

Primary: Changes in Intervention Response as Evaluated by the Clinical Global Impression of Change (CGIC) — 0; 0; 5; 2 Participants

Primary: Mini Mental State Examination (MMSE) Total Scores by Visit — 18.7; 20.8; 20.5; 20.5 Scores on a scale